Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy
Springer Verlag, Singapore
978-981-15-8178-6 (ISBN)
The book begins with an overview of various epigenetic modifying enzymes that are involved in cancer transition and progression; before exploring the potential of HDACs in cancer treatment. It provides a classification of HDAC inhibitors based on their structural attributes, and addresses HDAC-induced cytotoxicity..
Lastly, it discusses and assesses the rationale behind therapies that combine HDAC inhibitors with other anticancer agents to treat solid tumors. Given its scope, it offers a valuable resource for all researchers, clinicians, and students working in formulation, drug discovery, oncology, and personalized medicine.
Dr. Shabir Ahmad Ganai has formerly worked as Principal Investigator/Young Scientist in the University of Kashmir. He has over 9 years of working experience in the field of histone deacetylases and histone deacetylase inhibitors. He has published more than 24 articles in highly reputed international journals, 3 international book chapters and has authored a book. He is currently serving as a referee for various international journals like Scientific Reports, PLOS ONE, Medicinal Chemistry Research, Current Drug Targets, Current Topics in Medicinal Chemistry, and Journal of Agricultural and Food Chemistry (American Chemical Society Publications). He is a member of two international societies, including the Epigenetics Society.
Chapter 1_Epigenetic modifying enzymes. -Chapter 2_Epigenetic modifying enzymes implicated in cancer. -Chapter 3_Classification of histone deacetylases (HDACs). -Chapter 4_Implications of 18 HDAC isoforms in therapeutically monotonous cancers. –Chapter 5_Possible Mechanisms of HDACs in Cancer development.- Chapter 6_Different strategies employed for circumventing cancer resistance (chemo and radio) and mitigating toxicity. -Chapter 7_Limitations of conventional therapeutic regimens in treating cancer. -Chapter 8_Overview of epidrugs with special emphasis on HDAC inhibitors (HDACi).- Chapter 9_HDAC inhibitors as promising epidrugs for treating cancer. -Chapter 10_ HDAC inhibitors in anticancer monotherapy. -Chapter 11_Distinct groups of histone deacetylase inhibitors (HDACi) based on the structural distinction, HDACs targeted. -Chapter 12_Limited efficacy of HDAC inhibitor-based monotherapy. -Chapter 13_Resistance mechanisms generated by cancer cells against HDACi based monotherapy. -Chapter 14_ Toxicity issue of HDAC inhibitor based monotherapy. -Chapter 15_Combinatorial therapeutic strategies of HDACi. -Chapter 16_Designing Selective HDACi using computational and medicinal chemistry approach. -Chapter 17. Current therapeutic challenges and future directions.
| Erscheinungsdatum | 16.01.2021 |
|---|---|
| Zusatzinfo | 13 Illustrations, color; 14 Illustrations, black and white; XVII, 258 p. 27 illus., 13 illus. in color. |
| Verlagsort | Singapore |
| Sprache | englisch |
| Maße | 155 x 235 mm |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
| Studium ► 2. Studienabschnitt (Klinik) ► Humangenetik | |
| Naturwissenschaften ► Biologie ► Biochemie | |
| Naturwissenschaften ► Biologie ► Genetik / Molekularbiologie | |
| Schlagworte | Anticancer therapy • Combinatorial therapy • HDAC inhibitors • Histone Deacetylase • Therapeutic Intervention |
| ISBN-10 | 981-15-8178-9 / 9811581789 |
| ISBN-13 | 978-981-15-8178-6 / 9789811581786 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
